27
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective

ORCID Icon, , , &
Pages 483-492 | Received 06 Mar 2024, Accepted 17 May 2024, Published online: 05 Jun 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.